ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events

ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On June 28, 2018, Celgene Corporation and Acceleron Pharma Inc. issued a joint press release titled "Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes."

A copy of the press release is attached as Exhibit99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.


ACCELERON PHARMA INC Exhibit
EX-99.1 2 xlrn-20180628ex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1             CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS IN PHASE III ‘MEDALIST’ STUDY IN PATIENTS WITH LOW-TO-INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES Results showed significant improvement in red blood cell transfusion independence compared to placeboSafety profile generally consistent with previously published dataRegulatory submissions planned in the United States and Europe in the first half of 2019SUMMIT,…
To view the full exhibit click here

About ACCELERON PHARMA INC. (NASDAQ:XLRN)

Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.

An ad to help with our costs